ReviewEndocrinology and metabolism (Seoul, Korea)2014
Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology.
Review in Endocrinology and metabolism (Seoul, Korea), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Interpretable LightGBM model with SHAP analysis predicts non-excellent response to initial radioiodine therapy in differentiated thyroid carcinoma.Journal of applied clinical medical physics · 2026Article
- Research progress of bone metastases: From disease recognition to clinical practice.Frontiers in oncology · 2022Review
- Review
- Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research.Ecancermedicalscience · 2020Article
- FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.PloS one · 2019Article
- Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma.Nuclear medicine and molecular imaging · 2018Article
- Star-Shaped Intense Uptake of ¹³¹I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq.Endocrinology and metabolism (Seoul, Korea) · 2018Article
- LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.Molecular medicine reports · 2018Article
- Human sodium iodide transporter gene-mediated imaging and therapy of mouse glioma, comparison betweenOncology letters · 2018Article
- Molecular radiotheragnostics in thyroid disease.Clinical medicine (London, England) · 2017Article
- Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.AJR. American journal of roentgenology · 2017Review
- Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer.Medicine · 2017Observational
- FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Targeted Radionuclide Therapy of Human Tumors.International journal of molecular sciences · 2015Review
- I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer.BMC gastroenterology · 2015Article
- Articles in 'endocrinology and metabolism' in 2014.Endocrinology and metabolism (Seoul, Korea) · 2015Article
- Glycididazole sodium combined with radioiodine therapy for patients with differentiated thyroid carcinoma (DTC).International journal of clinical and experimental medicine · 2015Article
- Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iodide uptake across the membranes of thyroid follicular cells and cancer cells occurs through an active transport process mediated by the sodium-iodide symporter (NIS). The rat and human NIS-coding genes were cloned and identified in 1996. Evaluation of NIS gene and protein expression is critical for the management of thyroid cancer, and several approaches to increase NIS levels have been tried. Identification of the NIS gene has provided a means of expanding its role in radionuclide therapy and molecular target-specific theragnosis (therapy and diagnosis using the same molecular target). In this article, we describe the relationship between NIS expression and the thyroid carcinoma treatment using I-131 and alternative therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.